![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Publisher: Adis International
ISSN: 1173-8324
Source: Inpharma, Vol.1, Iss.1607, 2007-01, pp. : 13-13
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
GLP-1-based therapies yet to reach their peak potential
Inpharma, Vol. 1, Iss. 1656, 2008-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
GLP-2 beneficial in functional short bowel syndrome?
Inpharma, Vol. 1, Iss. 1284, 2001-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Substitute ACE inhibitors with valsartan in HF?
Inpharma, Vol. 1, Iss. 1363, 2002-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
RRM1-based tailored chemotherapy for NSCLC?
Inpharma, Vol. 1, Iss. 1432-1433, 2004-01 ,pp. :